Relmada Therapeutics (RLMD) Return on Capital Employed (2013 - 2026)
Relmada Therapeutics (RLMD) reported Return on Capital Employed of 39.75% for Q1 2026, up 21129.0% year-over-year from N/an in Q1 2025, and up 67.71% on a QoQ basis from 123.1% in Q4 2025.
Relmada Therapeutics (RLMD) has 14 years of Return on Capital Employed data on file, last reported at 39.75% in Q1 2026.
- Quarterly Return on Capital Employed rose 21129.0% year-over-year to 39.75% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 39.75% (up 21129.0% YoY) and the FY2025 annual result came in at 93.1%, up 4354.0% from the prior year.
- Return on Capital Employed rose to 39.75% in Q1 2026 per RLMD's latest filing, from 123.1% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 39.75% in Q1 2026 and bottomed at 451.66% in Q3 2025.
- The 5-year median for Return on Capital Employed is 113.76% (2023), against an average of 155.65%.
- The widest annual swing landed in 2025, when Return on Capital Employed slumped 28591 bps; it then soared 21129 bps in 2026.
- Tracing RLMD's Return on Capital Employed over 5 years: stood at 102.35% in 2022, then fell by 11 bps to 113.76% in 2023, then sank by 82 bps to 207.24% in 2024, then soared by 41 bps to 123.1% in 2025, then soared by 68 bps to 39.75% in 2026.
- Per Business Quant, the three latest RLMD Return on Capital Employed figures stand at 39.75% (Q1 2026), 123.1% (Q4 2025), and 451.66% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | -39.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.75% |
| Dec 31, 2025 | -123.10% |
| Sep 30, 2025 | -451.66% |
| Jun 30, 2025 | -366.11% |
| Mar 31, 2025 | -251.04% |
| Dec 31, 2024 | -207.24% |
| Sep 30, 2024 | -165.75% |
| Jun 30, 2024 | -133.95% |
| Mar 31, 2024 | -125.34% |
| Dec 31, 2023 | -113.76% |
| Sep 30, 2023 | -107.84% |
| Jun 30, 2023 | -111.45% |
| Mar 31, 2023 | -112.65% |
| Dec 31, 2022 | -102.35% |
| Sep 30, 2022 | -86.75% |
| Jun 30, 2022 | -79.58% |
| Mar 31, 2022 | -67.70% |
| Dec 31, 2021 | -88.48% |
| Sep 30, 2021 | -136.12% |
| Jun 30, 2021 | -93.12% |
| Mar 31, 2021 | -74.53% |
| Dec 31, 2020 | -55.67% |
| Sep 30, 2020 | -38.04% |
| Jun 30, 2020 | -28.30% |
| Mar 31, 2020 | -22.88% |
| Dec 31, 2019 | -30.66% |
| Jun 30, 2019 | -334.48% |
| Mar 31, 2019 | -1,356.38% |
| Dec 31, 2018 | -1,757.06% |
| Sep 30, 2018 | 154.09% |
| Mar 31, 2018 | -4,535.40% |
| Dec 31, 2017 | -428.19% |
| Sep 30, 2017 | -871.68% |
| Jun 30, 2017 | -339.39% |
| Mar 31, 2017 | -215.13% |
| Dec 31, 2016 | -159.04% |
| Sep 30, 2016 | -191.99% |
| Jun 30, 2016 | -192.41% |
| Mar 31, 2016 | -142.79% |
| Dec 31, 2015 | -140.51% |
| Sep 30, 2015 | -113.97% |
| Jun 30, 2015 | -162.16% |
| Mar 31, 2015 | -506.07% |
| Dec 31, 2014 | -980.27% |
| Sep 30, 2014 | 80.30% |
| Nov 30, 2013 | 157.20% |
| Aug 31, 2013 | 153.33% |
| May 31, 2013 | 222.38% |